Predictive and prognostic factors in RCC

Poster Session 48

**Location:** Room 7, Capital suite (level 3)

**Chairs:**
- A. Mattei, Luzern (CH)
- M. Oya, Tokyo (JP)
- B. Peyronnet, Rennes (FR)

**Aims and objectives of this session**
To discuss various predictive and prognostic factors in RCC.

**Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.**

**640**

**Predictive factor of lymph node metastases in patients with non-metastatic renal cell carcinoma; multi-center study**

**By:** Kim K.S.¹, Kim H.W.², Kim J.C.³, Kwak C.⁴, Kim Y.-J.⁵, Kang S.H.⁶, Byun S.-S.⁷, Kim S.H.¹, Hong S.-H.⁸

**Institutes:**
1. Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Dept. of Urology, Incheon, South Korea
2. St. Paul’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Dept. of Urology, Seoul, South Korea
3. Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea., Dept. of Urology, Bucheon, South Korea
4. Seoul National University College of Medicine, Seoul, Korea., Dept. of Urology, Seoul, South Korea
5. Chungbuk National University College of Medicine, Cheongju, Korea., Dept. of Urology, Cheongju, South Korea
6. Korea University School of Medicine, Seoul, Korea, Dept. of Urology, Seoul, South Korea
7. Seoul National University Bundang Hospital, Seongnam, Korea, Dept. of Urology, Seongnam, South Korea
8. College of Medicine, The Catholic University of Korea, Seoul, Korea, Dept. of Urology, Seoul, South Korea

**641**

**Long-term assessment of mortality patterns after surgical treatment for non-metastatic kidney cancer: A competing risk analysis**

**By:** Larcher A.¹, Muttin F.¹, Nini A.¹, Trevisani F.¹, Ripa F.¹, Cianflone F.¹, Carenzi C.¹, Dell’Oglio P.¹, Rigatti P.², Dehó F.¹, Montorsi F.¹, Capitanio U.¹, Bertini R.¹

**Institutes:**
1. IRCCS Ospedale San Raffaele, Urological Research Institute, Division of Oncology, Milan, Italy
2. Scientific Institute Istituto Auxologico Italiano, Department of Urology, Advanced Urotechnology Center, Milan, Italy

**642**

**External validation of the Mayo Clinic Stage, Size, Grade, and Necrosis score in patients with renal cell carcinoma and venous tumor thrombus**

**By:** Lorentz C.¹, Tai C.², Capitanio U.³, Carballido J.⁴, Ciancio G.⁵, Daneshmand S.⁶, Evans C.⁷, Gontero P.⁸, Haferkamp A.⁹, Hohenfellner M.¹⁰, Huang W.¹¹, Espínós E.¹², Martínez-Salamanca J.¹³, McKiernan J.¹⁴, Montorsi F.¹⁵, Pahernik S.¹⁶, Palou J.¹⁷, Pruith R.¹⁸, Russo P.¹⁹, Scherr D.²⁰, Spahn M.²¹, Terrone C.²², Tilki D.²³, Donoso C.²⁴, Vergho D.²⁵, Walten E.²⁶, Zigeuner R.²⁷, Libertino J.²⁸, Master V.¹

**Institutes:**
1. Emory University School of Medicine, Dept. of Urology, Atlanta, United States of America
2. University of California, Dept. of Epidemiology and Biostatistics, San Francisco, United States of America
3. University Vita-Salute, Dept. of Urology, Milan, Italy
4. Universidad Autónoma De Madrid, Dept. of Urology, Madrid, Spain
5. University of Miami, Dept. of Urology, Miami, United States of America
6. University of Southern California, Dept. of Urology, Los Angeles, United States of America
7. University of California-Davis, Dept. of Urology, Sacramento, United States of America
8. University of Turin, Dept. of Urology, Turin, Italy
9. University of Frankfurt, Dept. of Urology, Frankfurt, Germany
10. University of Heidelberg, Dept. of Urology, Heidelberg, Germany
11. New York University School of Medicine, Dept. of Urology, New York, United States of America
The prevalence of renal cancer detected by abdominal ultrasonography in asymptomatic individuals: A systematic review and meta-analysis to inform the case for a screening study

By: Rossi S.¹, Hsu R.¹, Blick C.², Goh V.³, Hanbury D.⁴, Nathan P.⁵, Nicol D.⁶, Fleming S.⁷, Sweeting M.⁸, Watson C.⁹, Wilson E.¹⁰, Stewart G.¹

Institutes: ¹Addenbrooke's Hospital, Dept. of Urology, Cambridge, United Kingdom, ²Royal Berkshire Hospital, Dept. of Urology, Reading, United Kingdom, ³Guy’s & St Thomas’ Hospitals NHS Trust, Dept. of Radiology, London, United Kingdom, ⁴Lister Hospital, Dept. of Urology, Stevenage, United Kingdom, ⁵Mount Vernon Cancer Centre, Dept. of Oncology, Northwood, United Kingdom, ⁶Royal Marsden Hospital, Dept. of Urology, London, United Kingdom, ⁷Ninewells Hospital, Centre for Forensic and Legal Medicine, Dundee, United Kingdom, ⁸University of Cambridge, Dept. of Public Health and Primary Care, Cambridge, United Kingdom, ⁹National Cancer Research Institute, Renal and Bladder Cancer Clinical Studies Group, London, United Kingdom, ¹⁰University of Cambridge, Cambridge Centre for Health Services Research, Cambridge, United Kingdom

Predictive and prognostic effect of inflammatory lymphadenopathies in renal cell carcinoma

By: Pecoraro A.¹, Larcher A.¹, Nini A.¹, Muttin F.¹, Stabile A.¹, Di Trapani E.¹, Carenzi C.¹, Trevisani F.¹, De Cobelli F.², Gabardi F.², Guazzoni G.³, Briganti A.³, Montorsi F.³, Bertini R.³, Capitanio U.³

Institutes: ¹IRCCS Ospedale San Raffaele, Urological Research Institute, Dept. of Oncology and Urology, Milan, Italy, ²IRCCS Ospedale San Raffaele, Dept. of Radiology, Milan, Italy, ³Humanitas Clinical and Research Centre, Dept. of Urology, Milan, Italy

Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: Results of an international multi-institutional study on 2189 patients


Institutes: ¹¹Hospital Universitario Infanta Sofia, Dept. of Urology, Madrid, Spain, ¹²Columbia University College of Physicians and Surgeons, Dept. of Urology, New York, United States of America, ¹³Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ¹⁴University of North Carolina, Dept. of Urology, Chapel Hill, United States of America, ¹⁵Memoria Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, ¹⁶Weill Cornell Medical Center, Dept. of Urology, New York, United States of America, ¹⁷University of Würzburg, Dept. of Urology, Würzburg, Germany, ¹⁸University of Eastern Piedmont, Dept. of Urology, Novara, Italy, ¹⁹Hospital Universitario Y Politécnico La Fe, Dept. of Urology, Valencia, Spain, ²¹Medical University of Graz, Dept. of Urology, Graz, Austria, ²²Lahey Clinic, Dept. of Urology, Burlington, United States of America

Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease

By: Wagener N.¹, Edelmann D.², Benner A.², Huck N.¹, Hutterer G.³, Zigeuner R.³, Borgmann H.⁴, Haferkamp A.⁵, Pahernik S.⁵, Wolff I.⁶, Krabbe L.⁷, Herrmann E.⁷, Vergho D.⁸, Mirvall C.⁹, Surcel
Non-metastatic renal cell carcinoma follow-up, recurrences and outcomes – a RECUR database analysis

By: Dabestani S. 1, Beisland C. 2, Gudmundsson E. 3, Stewart G. 4, Lam T. 5, Gietzmann W. 6, Zakikhani P. 7, Marconi L. 8, Williams S. 9, Powles T. 10, Van Werkhoven E. 11, Meijer R.P. 12, Ljungberg B. 13, Bex A. 14

Institutes: Lund University, Dept. of Clinical Sciences, Malmö, Sweden, 2Haukeland University Hospital, Dept. of Urology, Bergen, Norway, 3Landspitali University Hospital, Dept. of Urology, Reykjavik, Iceland, 4University of Cambridge, Academic Urology Group, Cambridge, United Kingdom, 5University of Aberdeen, Academic Urology Unit, Aberdeen, United Kingdom, 6Aberdeen Royal Infirmary, Dept. of Urology, Aberdeen, United Kingdom, 7Coimbra University Hospital, Dept. of Urology, Coimbra, Portugal, 8Queen Mary University of London, Barts Cancer Institute, London, United Kingdom, 9The Netherlands Cancer Institute, Dept. of Bioinformatics and Statistics, Amsterdam, The Netherlands, 10The Netherlands Cancer Institute, Division of Surgical Oncology, Department of Urology, Amsterdam, The Netherlands, 11Umeå University, Dept. of Surgical and Perioperative Sciences, Umeå, Sweden, 12University Medical Center Utrecht, Dept. of Urology, Utrecht, The Netherlands, 13University of Edinburgh, Dept. of Urology, Edinburgh, United Kingdom

Contemporary incidence and epidemiologic trends of brain metastases at renal cell carcinoma diagnosis

By: Gild P. 1, Von Landenberg N. 1, Sun M. 1, Develasco G. 2, Brastianos P. 3, Menon M. 4, Fisch M. 5, Chun F. 6, Nguyen P. 6, Trinh Q-D. 6, Choueiri T. 2

Institutes: Brigham and Women’s Hospital, Center For Surgery and Public Health and Division of Urologic Surgery, Boston, United States of America, 2Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America, 3Dana-Farber Cancer Institute, Dept. of Cancer Biology, Boston, United States of America, 4Henry Ford Hospital, VUI Center For Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America, 5University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, 6Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Dept. of Medical Oncology, Boston, United States of America

Utilization and outcomes of T2 partial nephrectomy: A US population based analysis of the national cancer database

By: Hamilton Z., Fero K., Bloch A., Field C., Han D., Derweesh I.

Institutes: Moores Cancer Center, Dept. of Urology, La Jolla, United States of America

Contact with renal sinus is a significant risk factor for metastasis in pT1 clear cell renal cell
Poster Session 48

carcinoma

Institutes: 1Tokyo Medical And Dental Graduate School, Dept. of Urology, Tokyo, Japan, 2Saitama Cancer Center, Dept. of Urology, Saitama, Japan, 3Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Dept. of Urology, Tokyo, Japan, 4Cancer Institute Hospital, Dept. of Urology, Tokyo, Japan, 5Tokyo Medical and Dental Graduate School, Dept. of Urology, Tokyo, Japan

Utility of chest x-ray in follow-up of pT1 renal cell carcinoma

Institutes: 1Cattinara Hospital, University of Trieste, Dept. of Urology, Trieste, Italy, 2Onze-Lieve-Vrouweziekenhuis, Dept. of Urology, Aalst, Belgium, 3University Hospital Careggi, Dept. of Urology, Florence, Italy

Organ confined renal cell carcinoma - are the current guidelines sufficient?

Institutes: 1University Medical Center, Dept. of Urology, Mainz, Germany, 2Hochtaunus Hospital Bad Homburg, Dept. of Urology, Bad Homburg, Germany, 3Vancouver Prostate Center, Dept. of Urology, Vancouver, Canada, 4University Medical Center, Dept. of Urology, Mannheim, Germany

Impact of hospital volume and surgeon volume on robot-assisted partial nephrectomy results: A multicenter study


Hospital activity and costs following partial nephrectomy: A comparison of surgical modalities using UK data
By: Camp C., O'Hara J., Hughes D., Adshead J.

Institutes: 1Hcd Economics, Dept. of Economics, Daresbury, United Kingdom, 2Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, Dept. of Urology, Stevenage, United Kingdom